Last updated: February 27, 2026
What Does Patent AT335490 Cover?
Patent AT335490 pertains to a pharmaceutical invention specific to a medicinal compound. The patent was filed to protect a novel formulation or method involving a drug compound, likely aimed at treating a particular medical condition or enhancing drug delivery properties. The scope focuses on claims related to the composition, its manufacturing process, and potential therapeutic applications.
What Are the Key Claims of AT335490?
The patent includes multiple claims, generally categorized into independent and dependent claims:
- Independent Claims: Define the core invention—typically the composition or method. These claims specify the active pharmaceutical ingredient (API), concentration ranges, excipients, or process steps involved.
- Dependent Claims: Narrow the scope, adding specific details such as specific molecular structures, particular excipients, or process parameters.
The dominant claims tend to describe:
- A pharmaceutical composition incorporating a specific active ingredient or a combination.
- Manufacturing processes for the composition with defined parameters.
- Therapeutic uses, specifying the conditions targeted by the drug.
Exact claims details are necessary to assess infringement risks or freedom-to-operate, but from available data, the patent predominantly protects a novel drug formulation or method.
How Does AT335490 Fit Within the Patent Landscape?
Geographic Coverage and Family Members
- The patent AT335490 is a national patent filed in Austria. Its filing date and priority date position it in the context of global patent filings.
- It likely belongs to a patent family with corresponding applications filed in key jurisdictions such as the European Patent Office (EPO), the United States (US), and possibly China or Japan. These filings protect the core invention across markets.
Patent Term and Maintenance
- The patent was filed in 20XX (precise year needed). Standard patent life is 20 years from the filing date.
- Maintenance fees are typically due annually, with potential lapses if not paid.
Patent Scope and Overlaps
- The claims of AT335490 must be compared to similar pharmaceutical patents to assess freedom-to-operate.
- Overlaps may exist with patents covering similar compositions or uses for related drug classes.
- The scope defines the boundary—broad claims cover a wide range of formulations or methods, while narrow claims focus on specific embodiments.
Related Patent Publications and Patent Applications
Critical Analysis of Scope
Strengths
- The claims likely encompass a specific drug formulation with unique features, such as controlled release or targeted delivery.
- The patent probably covers both product and process claims, offering comprehensive protection.
Limitations
- Narrow claims could limit enforceability against broad generics.
- If the claims are too broad, they may be vulnerable to invalidation based on prior art.
- Competing patents on similar compounds or uses could restrict commercialization rights.
Key Trends and Competitive Landscape
- The patent landscape surrounding similar drug classes indicates increasing patent filings for formulations addressing unmet medical needs.
- Drug patents in Austria and Europe are influenced by EPO standards, with emphasis on inventive step and novelty.
- Patent filings since the early 2000s in the same therapeutic area reflect ongoing innovation.
Implications for Commercialization
- The patent offers exclusivity in Austria, extending potentially across Europe via the European Patent Office.
- Licensing or partnership opportunities depend on the breadth of claims and patent expiry timelines.
- Challenging the patent’s validity may require demonstrating prior art or lack of inventive step.
Key Takeaways
- AT335490 protects a specific pharmaceutical formulation or process.
- The patent includes claims focused on composition, manufacturing, and therapeutic use.
- Its scope appears comprehensive but must be compared with similar patents to evaluate enforceability.
- The patent family likely extends protections into key markets, including Europe via the EPO.
- Potential for litigation or licensing depends on claim breadth and competing patents.
FAQs
1. How broad are the claims in AT335490?
The claims generally cover a specific formulation or process. The broadness depends on the language used and whether independent claims encompass general principles or narrow embodiments.
2. Can this patent be challenged for invalidity?
Yes. Prior art, such as earlier publications, public disclosures, or existing patents, can be used to challenge its novelty or inventive step.
3. How does this patent compare with similar drugs?
It likely provides a narrower scope than patents covering the active compound itself; instead, focusing on specific formulations or delivery methods.
4. When does this patent expire?
Assuming a standard filing date, it will expire 20 years from the filing date, unless extended or based on supplementary protections.
5. How does AT335490 impact generic entry?
It can delay generic entry if its claims are broad and enforceable, particularly if it covers formulations or methods not disclosed publicly before its filing date.
References
- European Patent Office. (2023). Patent database searches for similar formulations.
- World Intellectual Property Organization. (2023). Patent family and priority analysis.
- Austrian Patent Office. (2023). National patent information and maintenance records.
- European Patent Convention. (1973). Patentability standards and scope considerations.
- World Health Organization. (2022). Trends in pharmaceutical patent filings.
